Hagens Berman has announced a lead plaintiff deadline of August 17, 2026 for investors in Embecta Corp. who suffered substantial losses during the class period from November 25, 2025 to May 4, 2026. The pending class action alleges that Embecta and its management misled investors about the stability of its insulin pen needle business, which was actually experiencing competitive share loss and market volume softness. On May 5, 2026, the company reported a massive revenue decline, slashed its full-year 2026 adjusted EPS guidance by approximately 43% at the midpoint, and cut its quarterly dividend by 93% from $0.15 to $0.01 per share, causing the stock to drop 57.8% in a single day. The firm is investigating whether Embecta’s prior assurances were materially false and misleading.
Embecta CorpCompany slashed guidance and dividend, stock dropped 57.8% on May 5, 2026.
